Determine antiviral drug resistance by DNA sequencing.
Polymerase Chain Reaction/Sequencing
Within 10 days
Lavender (EDTA), pink (K2EDTA), serum separator tube, or plasma preparation tube.
Separate serum or plasma from cells within 24 hours. Transfer 2 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Ambient: 72 hours; Refrigerated: 1 week; Frozen: 6 weeks
Both the HBV RT polymerase and the HBsAg encoding regions are sequenced. Resistance and surface antigen mutations are reported. In addition, the major HBV genotypes are identified. Mutations in viral sub-populations below 20 percent of total may not be detected.
Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
This test may be unsuccessful if the HBV viral load is less than log 3.0 or 1,000 IU/mL of plasma.
|Component Test Code*||Component Chart Name||LOINC|
|2001568||HBV Surface Antigen Mutations by Seq||32366-7|
|2001569||Hepatitis B Genotype by Seq||32366-7|
|2001570||HBV RT Polymerase Mutations by Seq||49883-2|
- HBsAg mutations
- HBV drug resistance testing
- HBV Genotype
- HBV Genotyping
- HBV Resistance
- HBV Resistance Sequencing
- HBV Sequencing
- Hepatitis B Drug Resistance Panel